Literature DB >> 9891725

Lymphoproliferative and myeloproliferative disorders.

C J Savage1.   

Abstract

Nomenclature regarding neoplasia of the hematopoietic and lymphoid tissues in the horse is confusing. This article will clarify terminology, and discuss the individual lymphoproliferative and myeloproliferative disorders recognized in the horse. Diagnostic techniques that are useful in cases in which hematopoietic or lymphoid tissue neoplasia are suspected include histochemical staining profiles, bone marrow aspiration, and bone marrow biopsy.

Entities:  

Mesh：

Year:  1998        PMID： 9891725     DOI： 10.1016/s0749-0739(17)30187-6

Source DB:  PubMed          Journal:  Vet Clin North Am Equine Pract        ISSN： 0749-0739            Impact factor:   1.792


  5 in total

1.  A case report of T-cell lymphoma in a horse.

Authors:  A Gavazza; G Lubas; V Turinelli; I Ghernati; A J Delgadillo
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

2.  Oxidative stress in dogs with multicentric lymphoma: Effect of chemotherapy on oxidative and antioxidant biomarkers.

Authors:  Nathieli B Bottari; Thiago D Munhoz; Vanessa D Torbitz; Alexandre A Tonin; Letícia A Anai; Lívia M S Semolin; Paulo C Jark; Yãnaí S Bollick; Rafael N Moresco; Raqueli T França; Sonia T A Lopes; Lenita M Stefani; Mirela Tinucci-Costa; Aleksandro S Da Silva
Journal:  Redox Rep       Date:  2015-08-14       Impact factor: 4.412

3.  Pelvic lymphoma as a cause of urethral compression in a mare.

Authors:  Julia B Montgomery; Wendy M Duckett; Andrea C Bourque
Journal:  Can Vet J       Date:  2009-07       Impact factor: 1.008

Review 4.  Hematopoietic neoplasias in horses: myeloproliferative and lymphoproliferative disorders.

Authors:  Ana Muñoz; Cristina Riber; Pablo Trigo; Francisco Castejón
Journal:  J Equine Sci       Date:  2010-01-19

Review 5.  A review of current knowledge of myeloproliferative disorders in the horse.

Authors:  Katy Satué; Juan Carlos Gardon; Ana Muñoz
Journal:  Acta Vet Scand       Date:  2021-02-23       Impact factor: 1.695
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.